TC BioPharm (Holdings) PLC announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000. This undertaking, which will utilize its current infrastructure, will provide a cost reduction of 85% per patient treatment. The Company expects to implement the improved manufacture process into its current facility in the next 24 months.